Managing cardiovascular risk inpatients with metabolic syndrome
References (21)
- et al.
The metabolic syndrome: A vascular perspective
Eur J Intern Med.
(2005) - et al.
Metabolic syndrome and risk of cardiovascular events after myocardial infarction
J Am Coll Cardiol
(2005) - et al.
Cardiovascular risk assessment in metabolic syndrome: View from PROCAM
Endocrinol Metab Clin North Am.
(2004) Estimating cardiovascular disease risk and the metabolic syndrome: A Framingham view
Endocrinol Metab Clin North Am.
(2004)- et al.
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome
Am J Cardiol.
(2003) - et al.
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-yearexperience from the RIO-Europe study
Lancet
(2005) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol inadults (Adult Treatment Panel 111). Final report
Circulation
(2002)Understanding diabetes: diabetes hypertension, and cardiovascular disease
(October 19, 2005)- et al.
Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey
JAMA
(2002) - et al.
Increasing prevalence of the metabolic syndrome among U.S. adults
Diabetes Care
(2004)
Cited by (6)
Chapter 7 Cannabinoid Receptor CB1 Antagonists. State of the Art and Challenges
2009, Vitamins and HormonesCitation Excerpt :In another recent trial aimed to assess the effects of rimonabant in overweight patients with dyslipidemia (Déspres et al., 2005), in the majority of patients completing 12 months of study and receiving 20 mg/day of rimonabant, the levels of triglycerides significantly decreased, whereas HDL cholesterol increased compared with placebo group. Furthermore, the prevalence of metabolic syndrome, a collection of factors (abdominal adiposity, hypertriglyceridemia, low HDL cholesterol, hypertension, and fasting hyperglycemia) increasing the risk of type 2 diabetes and cardiovascular disease (Nesto, 2005), was reduced in the same subset of patients (Pi‐Sunyer et al., 2006). Indeed, the population of patients matching the National Cholesterol Education Program's Adult Treatment Panel III (NCEP‐ATPIII) criteria for the metabolic syndrome (54% of the total), fell to the half of baseline after they received 20 mg rimonabant (Déspres et al., 2005).
Genetic Risk, Adherence to a Healthy Lifestyle, and Ischemic Heart Disease
2019, Current Cardiology ReportsImprovement of food practices in a population with cardiovascular risk factors after a nutrition education program
2012, Revista Espanola de Nutricion ComunitariaIron overload potentiates diet-induced hypercholesterolemia and reduces liver ppar-α expression in hamsters
2012, Journal of Biochemical and Molecular ToxicologyRimonabant: Just an antiobesity drug? Current evidence on its pleiotropic effects
2007, Molecular PharmacologyRole of hyperglycaemia in pathogenesis of diabetic cardiovascular disease
2007, Vascular Disease Prevention